| |
Out-of-date translations |
|
|
|
| The translations for
some VISs on our website are from previously published English-language
versions that have since been updated. Unfortunately, IAC is not always
able to obtain translations as updates are issued. Please ensure that your
patients receive information consistent with the current of
the following VISs. |
|
|
|
NEPALI TRANSLATION OF THE JULY 18, 2007 HEPATITIS B VIS |
|
|
|
|
|
|
| These translations do not contain the following
CDC update: |
|
| • |
|
Minor language changes throughout. |
|
|
|
| • |
|
Epidemiologic statistics in section 1. |
|
|
|
| • |
|
Inclusion of the routine schedules and addition of recommendation for adults with diabetes in section 3. |
|
|
|
| • |
|
Note about waiting to donate blood following vaccination in section 4. |
|
|
|
|
| NEPALI TRANSLATION OF THE MARCH 13, 2008 MMR VIS |
|
|
|
|
|
|
| This translation does not contain the following
CDC updates: |
|
| • |
|
Section 2, sentence has been
added noting that children younger than 12 months who are
traveling out of the country should get a dose of MMR; |
|
|
|
| • |
|
Section 3, a note has been added asking the patient to tell their provider if they received another vaccine within the
past 4 weeks (to alert the provider of the possibility of administering two live vaccines too close together); |
|
|
|
| • |
|
Section 4, the statement that minor problems usually occur 7-12 days after the shot was changed to the more accurate 6-14
days; and |
|
|
|
| • |
|
Box noting the risk of adverse events following MMRV
was removed, as it is not relevant for patients receiving
MMR. |
|
|
|
| • |
|
This VIS is the
first to feature a 2D barcode, which will allow providers to
scan selected information into the patient's record or into
an immunization information system. |
|
|
|
| NEPALI TRANSLATION OF THE JANUARY 1, 2000 POLIO - IPV VIS |
|
|
|
|
|
|
| This translation does not contain the following
CDC update: |
|
| • |
|
This edition does not differ significantly from the previous edition, particularly with regard to contraindications and
adverse events. CDC encourages use of a new VIS upon publication; however, existing stocks of the previous edition may be
used up. |
|
A-Z
